Loading...
XNAS
DXCM
Market cap34bUSD
Aug 28, Last price  
91.00USD
Name

Dexcom Inc

Chart & performance

D1W1MN
XNAS:DXCM chart
P/E
41.06
P/S
7.37
EPS
2.22
Div yield, %
Shrs. gr., 5y
0.78%
Rev. gr., 5y
19.33%
Revenues
Net income
CFO

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
IPO date
Apr 14, 2005
Employees
7,500
Domiciled in
US
Incorporated in
US

Valuation

No data to show